Abiopharma

BioRestorative Announces Share Repurchase Program

New Form 8-K - FEMASYS INC Filed: 2025-06-17 AccNo: 0001140361-25-022762 Size: 183 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - LISATA THERAPEUTICS, INC. Filed: 2025-06-17 AccNo: 0000320017-25-000039 Size: 11 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

- Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

New Form 8-K - Syra Health Corp Filed: 2025-06-17 AccNo: 0001641172-25-015349 Size: 197 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Resumes Trading on NYSE American

New Form 8-K - Lyell Immunopharma, Inc. Filed: 2025-06-17 AccNo: 0001193125-25-141795 Size: 147 KB Item 8.01: Other Events

New Form 6-K - PolyPid Ltd. Filed: 2025-06-17 AccNo: 0001213900-25-054964 Size: 309 KB

New Form 8-K - IGC Pharma, Inc. Filed: 2025-06-17 AccNo: 0001185185-25-000657 Size: 133 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits